As of 11:16am ET
| -0.061 / -1.57%|
The 2 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 5.25, with a high estimate of 5.50 and a low estimate of 5.00. The median estimate represents a +37.43% increase from the last price of 3.82.
The current consensus among 2 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.